Tags

Type your tag names separated by a space and hit enter

Who benefits most from THC:CBD spray? Learning from clinical experience.

Abstract

Patients with multiple sclerosis (MS) represent a diverse and heterogeneous population varying in terms of disease type, its severity and variable progression/time-course, and with regard to the wide range of presenting symptoms. Consequently, detailed experience with individual patients is important to provide examples of therapy to specific patient types. In this article, real-life data from clinical practice showing specific aspects relating to use of 9-delta-tetrahydocannabinol and cannabidiol (THC:CBD) oromucosal spray (Sativex®) in patients with moderate to severe spasticity resistant to usual therapy will be presented. Three common clinical scenarios will be considered: MS patients with resistance to usual spasticity therapies; patients with impairment in MS spasticity symptoms; MS patients with relevant impairment in quality of life/activities of daily living (QoL/ADL). These case reports highlight the diverse nature of the MS spasticity population and they show the possible usefulness of THC:CBD oromucosal spray in individual patients with moderate to severe spasticity resistant to existing therapies, within the frame of use approved after large clinical trial results. Perhaps the most important finding is the possibility of obtaining relevant improvements in QoL/ADL in some patients with resistant MS spasticity, allowing them to engage back in physical and social activities.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    Marianne-Strauss-Klinik, Behandlungszentrum Kempfenhausen, Berg, Germany.

    Source

    European neurology 71 Suppl 1: 2014 pg 10-5

    MeSH

    Activities of Daily Living
    Adult
    Aged
    Cannabidiol
    Dronabinol
    Drug Combinations
    Female
    Humans
    Magnetic Resonance Imaging
    Male
    Middle Aged
    Multiple Sclerosis
    Muscle Spasticity
    Oral Sprays
    Parasympatholytics
    Plant Extracts
    Quality of Life
    Severity of Illness Index
    Spinal Cord
    Treatment Outcome

    Pub Type(s)

    Case Reports
    Journal Article

    Language

    eng

    PubMed ID

    24457847

    Citation

    Koehler, Jürgen. "Who Benefits Most From THC:CBD Spray? Learning From Clinical Experience." European Neurology, vol. 71 Suppl 1, 2014, pp. 10-5.
    Koehler J. Who benefits most from THC:CBD spray? Learning from clinical experience. Eur Neurol. 2014;71 Suppl 1:10-5.
    Koehler, J. (2014). Who benefits most from THC:CBD spray? Learning from clinical experience. European Neurology, 71 Suppl 1, pp. 10-5. doi:10.1159/000357743.
    Koehler J. Who Benefits Most From THC:CBD Spray? Learning From Clinical Experience. Eur Neurol. 2014;71 Suppl 1:10-5. PubMed PMID: 24457847.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Who benefits most from THC:CBD spray? Learning from clinical experience. A1 - Koehler,Jürgen, Y1 - 2014/01/22/ PY - 2014/1/25/entrez PY - 2014/1/25/pubmed PY - 2014/9/13/medline SP - 10 EP - 5 JF - European neurology JO - Eur. Neurol. VL - 71 Suppl 1 N2 - Patients with multiple sclerosis (MS) represent a diverse and heterogeneous population varying in terms of disease type, its severity and variable progression/time-course, and with regard to the wide range of presenting symptoms. Consequently, detailed experience with individual patients is important to provide examples of therapy to specific patient types. In this article, real-life data from clinical practice showing specific aspects relating to use of 9-delta-tetrahydocannabinol and cannabidiol (THC:CBD) oromucosal spray (Sativex®) in patients with moderate to severe spasticity resistant to usual therapy will be presented. Three common clinical scenarios will be considered: MS patients with resistance to usual spasticity therapies; patients with impairment in MS spasticity symptoms; MS patients with relevant impairment in quality of life/activities of daily living (QoL/ADL). These case reports highlight the diverse nature of the MS spasticity population and they show the possible usefulness of THC:CBD oromucosal spray in individual patients with moderate to severe spasticity resistant to existing therapies, within the frame of use approved after large clinical trial results. Perhaps the most important finding is the possibility of obtaining relevant improvements in QoL/ADL in some patients with resistant MS spasticity, allowing them to engage back in physical and social activities. SN - 1421-9913 UR - https://www.unboundmedicine.com/medline/citation/24457847/Who_benefits_most_from_THC:CBD_spray_Learning_from_clinical_experience_ L2 - https://www.karger.com?DOI=10.1159/000357743 DB - PRIME DP - Unbound Medicine ER -